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1. Introduction
The basis of information transfer in the mammalian central nervous system (CNS) consists of 
excitation and inhibition of neuronal networks. The messengers responsible for propagating 
these excitatory and inhibitory actions are amino acid neurotransmitters [1]. The principal 
excitatory neurotransmitter is glutamate, while the principle inhibitory neurotransmitter is 
gamma-aminobutyric acid (GABA). Coordination between these two principal neurotrans-
mitters ensures adequate rhythmic activity, which may involve either a single neuron or mul-
tiple neuronal groups, thus altering synaptic plasticity and ensuring a normal functioning 
of CNS [2]. As this spatiotemporal framework of different patterns in neural oscillations is 
essential for information processing throughout the brain [3], the deviations in normal activ-
ity of either system or their interactions are associated with a number of neurological and 
psychiatric diseases [4].
The GABA/glutamate functional balance could be achieved by homeostatic control of 
presynaptic elements such as glutamate and GABA release, which could be the result 
of changes in their metabolism (synthesis or degradation involving various enzymes), 
compartmentation, and recycling (involving plasma transporters) and in the amounts of 
transmitters available for release from synaptic vesicles (involving vesicular transport-
ers). However, it is generally considered that homeostatic plasticity mechanisms in the 
brain are mediated primarily by regulation of expression and function of glutamate and 
GABA receptors [5].
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2. GABA and its receptors
Every third chemical synapse in the brain uses neurotransmitter GABA as an integral part of 
the neurotransmission process. GABA mediates its effects via two types of receptors: iono-
tropic GABA
A
 and metabotropic GABA
B
 receptors [6]. Although a third type of GABA recep-
tor with pharmacological specificities has been identified, the term GABAС has not received broad consensus among experts. Additionally, the International Union of Basic and Clinical 
Pharmacology (IUPHAR) has classified GABA
C





 receptors generally contain chloride ion channels but can, in varying degrees, also 
contain calcium, sodium, and potassium channels. GABA
A
 receptors mediate the majority of 
GABA inhibitory actions in the CNS [4]. They are pentameric transmembrane receptors made 
up of 5 subunit proteins that form an ion channel selectively permeable to chloride anions. 
Although mainly localized on postsynaptic membranes, they can also be found extrasyn-
aptically, especially GABA
A
 receptors containing α4, α5, or α6 subunits [8]. Unexpectedly, 
GABA
A
 receptors have also been found on glial cells, potentially providing adaptational sup-
port for adjacent neurons [9]. Activation of GABA
A
 receptors leads to a change in the con-
formational state of associated ion channels, resulting in increased permeability to chloride 
ions. GABAergic mechanisms are also involved in metabolic processes [10], and a negative 
correlation between the intensity of GABAergic neurotransmission and metabolic processes 
in cerebral tissue has been established. So far, 19 subunits of GABA
A
 receptors have been 
cloned and classified into several structurally related subfamilies (α 1–6, β 1–3, γ 1–3, δ, ε, θ, 
π, ρ 1–3). The most frequently found GABA
A
 receptor composition is an aggregate composed 
of two α, two β, and one γ subunit [4]. Receptors that, in addition to two α and two β subunits, 
contain some other non-γ subunit are rare. Receptors composed only of α and β isoforms 
also exist. The subunit composition determines the functional and pharmacological proper-
ties of GABA
A
 receptors. For example, α1 GABA
A
 receptors mediate sedative and anticonvul-
sant actions, whereas the α2 subunit is responsible for anxiolytic action of benzodiazepines. 
Zolpidem, a commonly prescribed sedative for sleep initiation, has a high binding affinity for 
GABA
A
 receptors containing the α1 subunit [11].
GABA action through GABA
A
 receptors results in chloride channel opening and increased 
postsynaptic membrane permeability. In addition to the well-determined benzodiazepine 
binding site, at least 13 different and structurally specific sites on the GABA
A
 receptors have 
been identified: (1) GABA and other agonist-binding sites, as well as competitive antago-
nists; (2) picrotoxin site near ion channel; (3) barbiturates binding site; (4) neuroactive steroids 
binding site; (5) ethanol binding site; (6) inhalation anesthetics stereoselective binding sites; 
(7) furosemide diuretic binding site; (8) Zn2+ ion binding site; (9) other divalent cation binding 
sites; (10) La3+ ions site; (11) sites for phosphorylation of specific protein kinases; (12) phos-
pholipid-binding sites; and (13) sites involved in interaction of GABA
A
 receptor and micro-
tubules, which promote receptor grouping on postsynaptic membranes [12]. Modulators of 
GABA
A
 receptor complex interact with these binding sites in three possible ways: positive 
allosteric modulators that potentiate chloride ion flux (agonists), negative modulators that 
reduce GABA-induced chloride ion flux (inverse agonists), and neutral allosteric modulators 
that competitively block the effects of these two types of agonists-antagonists.
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On the other hand, GABA
B
 metabotropic receptors, characterized by stereoselective ligand (−)
baclofen, belong to the seven transmembrane G-protein-coupled receptor superfamily. They 
are pre- and postsynaptic G-protein-coupled receptors that negatively modulate adenylyl 
cyclase and inositol triphosphate synthesis. Heterodimeric structure as a result of GABAB1 
and GABAB2 subunit assembly is necessary for appropriate GABA
B
 receptor function. The 
extracellular domain of the GABAB1 subunit contains GABA-binding site, whereas GABAB2 
subunit is important for the interaction with the G-proteins. GABA
B
 receptor activation pro-
duces a cascade of signals that result in activation and/or inhibition of voltage-dependent 
calcium channels. GABA
B
 receptor is located both centrally and peripherally, particularly in 
the thalamus, brain stem nuclei, and spinal cord. Depending on the localization of GABA
B
 
receptors, GABA-mediated inhibitory influences can be potentiated (postsynaptic receptors, 
presynaptic heteroreceptors on glutamatergic endings) or reduced (autoreceptors) [13, 14]. 
GABAB receptor function affects behavior, learning, and memory, and therefore their phar-
macological targeting may be beneficial in various neuropsychiatric disorders [15, 16].
3. Glutamate and its receptors
Glutamate, the most abundant neurotransmitter in vertebrates and precursor of GABA, is pres-
ent in over 90% of all synaptic connections in the human brain and is essential for a wide variety 
of functions [17]. Over 20 types of mammalian glutamate receptors exist, generally classified 
into two main categories: voltage-sensitive (ionotropic) and ligand-sensitive (metabotropic) 
receptors. Ionotropic receptor channels are formed from various protein subunits assembled 
in heterotetrameric or homotetrameric receptors. The three types of ionotropic receptors are 
N-methyl-d-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA), and kainic acid receptors. The discovery of these agonists, after which the receptors 
were originally named, led to the detection of other receptor agonists and antagonists [18].
The binding of glutamate to NMDA receptors (NMDARs) results in the opening of a nonse-
lective cation channel. The opening and closing of the channel are primarily gated by ligand 
binding but are also voltage-dependent. Extracellular magnesium and zinc ions can bind to 
specific sites on the receptor, blocking the passage of other cations through the open ion chan-
nel. However, depolarization of the neuronal cell dislodges and repels these ions from the 
pore, therefore allowing a voltage-dependent influx of sodium and calcium ions and efflux of 
potassium ions [19]. The NMDA receptor is primarily a ligand-gated channel, but it does dis-
play weaker voltage-dependent modulation of the ligand-dependent gating. NMDA requires 
co-activation by two ligands: glutamate and either d-serine or glycine [20]. Furthermore, 
NMDA receptors are divided into subtypes, depending on their intracellular protein struc-
ture, NR1, NR2, and NR3. NR1 consists of eight different subunits originating from a single 
gene via alternative splicing. NR2 has four subunits (A–D), and NR3 has two subunits (A and B). 
NMDA receptors are highly expressed on both neurons and astrocytes [21]. NMDA signal-
ing is crucial for learning, memory, recovery from injury, and brain plasticity. It is especially 
important for proper functioning of the hippocampus [22]. In pathological circumstances, 
overactivation of NMDA receptors can lead to excitotoxicity, involved in some neurodegen-
erative disorders such as Alzheimer’s, Parkinson’s, and Huntington’s disease [23–25].
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AMPA receptors (AMPAR) are composed of four types of subunits, designated as GluA1, 
GluA2, GluA3, and GluA4 [26]. These receptors are heterotetrameric, containing GluA2 
and either GluA1, GluA3, or GluA4 subunits in a “dimer of dimers” structure [27, 28]. Each 
AMPAR consists of four subunits which make up four binding sites to which an agonist (such 
as glutamate) can bind. The channel opens when two binding sites are simultaneously occu-
pied, and the current increases as more binding sites become occupied [29]. Once opened, the 
channel may undergo rapid desensitization and current termination. Since AMPARs open and 
close quickly (1 ms), they are responsible for fast excitatory synaptic transmission in the CNS 
[30]. The GluA2 subunit regulates whether the AMPAR is permeable to calcium and other 
cations, such as sodium and potassium. If receptor does not contain a GluA2, the AMPAR will 
be permeable to calcium, sodium, and potassium. Both NMDA and AMPA ion channels are 
important for plasticity and synaptic transmission at many postsynaptic membranes.
Kainate receptors (KAR) are heteromeric receptors assembled from four subunits, formerly 
referred to as GluR5, GluR6, GluR7, KA1, and KA2 but now named GluK1, GluK2, GluK3, GluK4, 
and GluK5, and grouped into low affinity (GluK1–3) and high affinity (GluK4–5) receptors. Each 
subunit has a large extracellular N-terminal domain, four helical transmembrane domains (M1–M4), 
and an intracellular C-terminal domain. GluK1–3 subunits can form both homomeric and het-
eromeric receptors, but GluK4 and GluK5 subunits can form only heteromeric functional ion 
channels together with GluK1–3 subunits. Despite their ion channel structure, KAR can also acti-
vate metabotropic signaling through noncanonical G-protein-coupled cascade. They are widely 
distributed in the brain and can be localized at pre-, post-, and/or extrasynaptic sites. Although 
KAR are less studied than AMPAR or NMDAR, it is not known that they are multifunctional 
neuronal modulators which play significant roles in health and disease [31].
Metabotropic glutamate receptors (mGluR) have a G-protein-linked receptor structure consist-
ing of seven transmembrane domains with an extracellular N-terminal and an intracellular 
COOH terminal. When glutamate binds to a metabotropic receptor, it activates a postsynaptic 
intracellular G-protein, which eventually results in the opening of a membrane channel for sig-
nal transmission. Furthermore, G protein activation also triggers functional changes in the cyto-
plasm, resulting in gene expression and protein synthesis. For this reason, mGluR is generally 
considered slower acting channels than the ionotropic glutamate receptors. To date, three groups 
of mGluR exist. Group I receptors are coupled with phospholipase C, producing diacylglycerol 
and inositol triphosphate as second messengers. They are mainly expressed on the postsynaptic 
membrane. Group I receptors are involved in learning and memory, addiction, motor regula-
tion, and Fragile X syndrome [32]. Groups II and III are negatively coupled to adenylyl cyclase. 
Impaired functioning of group II metabotropic receptors has been linked to anxiety, schizophre-
nia, and Alzheimer’s disease. Group III metabotropic receptors also inhibit neurotransmitter 
release but are positioned presynaptically. They are found within the hippocampus and hypo-
thalamus and may play a role in Parkinson’s disease and anxiety disorders [33].
4. Conclusion and clinical implications
The adequate coordination of GABA and glutamate is essential to the normal functioning for 
the most complex brain processes. Decreased or increased GABA activity is associated with a 
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number of neurological and psychiatric diseases. The GABAergic synapse is the site of action 
of several different classes of drugs that modulate inhibitory neurotransmission and are used 
in the pharmacotherapy of anxiety and sleep disorders, epilepsy, alcohol withdrawal, and 
induction and maintenance of anesthesia [34]. Moreover, glutamate dysfunction is also corre-
lated with a wide range of nervous system disorders, such as Alzheimer’s disease, and neuro-
psychiatric disorders, including schizophrenia, pain disorders, drug addiction, and traumatic 
brain and spinal cord injuries [35]. Given the importance of equilibrium of these two systems 
for neuronal excitability, synaptic plasticity, and cognitive functions such as learning and 
memory, as well as its involvement in the mood, feeding behavior, reproductive functions, 
pain sensitivity, aging, etc. [36], it is not surprising that the development of current and pro-
spective pharmaceuticals, including anxiolytics, antidepressants, antipsychotics, antiepilep-
tics, antidementia, and many other drugs, relies increasingly on GABA/glutamate balance.
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